Why was Keytruda a groundbreaking approval?
In October 2014, the FDA granted accelerated approval to Keytruda (pembrolizumab), a monoclonal antibody that blocks the PD-1 receptor [1]. This was a significant milestone in the treatment of cancer, particularly non-small cell lung cancer (NSCLC) and melanoma.
How did Keytruda's approval differ from traditional cancer treatments?
Keytruda's approval marked a shift away from traditional chemotherapy and toward immunotherapy, which harnesses the power of the immune system to attack cancer cells [2]. This approach has been shown to have a more favorable safety profile and improved efficacy in some patients.
What impact did Keytruda's approval have on cancer treatment?
The FDA's approval of Keytruda paved the way for the development of additional checkpoint inhibitors, transforming the treatment landscape for various types of cancer [3]. As a result, patients with previously limited treatment options now have access to more targeted and effective therapies.
Sources:
[1] https://www.drugs.com/history/keytruda.html
[2] https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
[3] https://www.drugpatentwatch.com/brands/Keytruda/pembrolizumab
Note: The initial FDA approval date for Keytruda was October 4, 2014.